Remove Clinical Trials Remove Generic Drugs Remove Pharma Companies Remove Vaccine
article thumbnail

Should we be worried about pharma’s supply chain?

World of DTC Marketing

Ironically, in later times, the intense competition for out-of-patent drugs has subsided, which has led to spiraling rises in generic drug prices and shortages. Most of these generics are produced outside the US and recently there have been numerous recalls of generic drugs because of the failure of quality control.

article thumbnail

European Commission vs Big Pharma, or profit vs access?  

Drug Discovery World

Regulatory data protection (RDP) period RDP refers to the time when generic drug makers cannot refer to an innovator drug’s data to obtain a marketing authorisation 2. This looks like it may change shape in the future for the region, if the proposal put forward by the commission is adopted.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Katie Porter attacks pharma

World of DTC Marketing

So where to start… Congresswoman Porter may want to look at the percentage of generic drugs available virus branded (89%). I have worked with and stayed in contact with some R&D people within pharma and they have a different answer. In pharma R&D returns have declined to 1.8 percent—a slight decrease of 0.1

In-Vivo 187
article thumbnail

India: Why is the country ramping up drug discovery research?

Drug Discovery World

According to a report by Deloitte, globally India is the third largest in the world by volume and 11th by value, comprising over 3,000 pharma companies and 10,500 manufacturing facilities 2. Similarly, The Times of India says that branded generic medicines have “long fuelled India’s pharmaceutical exports” 4.

article thumbnail

‘Right shoring’ API production in Europe

Pharmaceutical Technology

During the pandemic, the shortage of basic drugs such as paracetamol in key EU countries led to growing calls to push local drug manufacturing to ensure a smooth supply and to minimise shortages. Despite having large biopharmaceutical companies on home ground, the UK and France experienced major shortages and supply chain issues.